You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 72 No. 4, October 1964 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (58)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Corneal Toxicity of Cytosine Arabinoside

HERBERT E. KAUFMAN; JOSEPH A. CAPELLA; EMILY D. MALONEY; JAMES E. ROBBINS; GEORGE M. COOPER; MAIJA H. UOTILA

Arch Ophthalmol. 1964;72(4):535-540.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Antiviral agents are, in many ways, similar to antibiotics. They inhibit virus multiplication and can make the use of corticosteroids safer by preventing the reactivation of latent virus and controlling the tendency of virus to multiply in the presence of corticosteroids. Like antibiotics, resistance to these agents can develop and the agents may have some effect on the host. Cytosine arabinoside (CA) is a therapeutically active antiviral agent which has the ability to alter the course of viral and cell multiplication.1 In addition to being able to cure experimental herpes simplex keratitis, CA has been extremely useful in treating patients with herpetic keratitis which is resistant to therapy by idoxuridine (5-iodo-2'-deoxyuridine, IDU).2 Although CA is more soluble than idoxuridine and allows preparations to be used less frequently than idoxuridine, it has the disadvantage of producing, under some circumstances, a reversible corneal toxicity. Corneal toxicity was first observed in . . . [Full Text PDF of this Article]


Author Affiliations

Gainesville, Fla.

Division of Ophthalmology, University of Florida College of Medicine.


Footnotes

Submitted for publication April 9, 1964.

This paper was supported by United States Public Health Service grant NB 03538-03 from the National Institute of Neurological Diseases and Blindness of the National Institutes of Health.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1964 American Medical Association. All Rights Reserved.